EP0105360A4 - ANTIBODIES WITH TWICE SPECIFICITY, THEIR PRODUCTION AND USE. - Google Patents

ANTIBODIES WITH TWICE SPECIFICITY, THEIR PRODUCTION AND USE.

Info

Publication number
EP0105360A4
EP0105360A4 EP19830901672 EP83901672A EP0105360A4 EP 0105360 A4 EP0105360 A4 EP 0105360A4 EP 19830901672 EP19830901672 EP 19830901672 EP 83901672 A EP83901672 A EP 83901672A EP 0105360 A4 EP0105360 A4 EP 0105360A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
preparation
uses therefor
dual specificities
specificities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19830901672
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0105360A1 (en
Inventor
Joanne Martinis
Richard M Bartholomew
Gary S David
Thomas H Adams
James M Frincke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of EP0105360A1 publication Critical patent/EP0105360A1/en
Publication of EP0105360A4 publication Critical patent/EP0105360A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP19830901672 1982-04-12 1983-04-12 ANTIBODIES WITH TWICE SPECIFICITY, THEIR PRODUCTION AND USE. Ceased EP0105360A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36778482A 1982-04-12 1982-04-12
US367784 1982-04-12

Publications (2)

Publication Number Publication Date
EP0105360A1 EP0105360A1 (en) 1984-04-18
EP0105360A4 true EP0105360A4 (en) 1986-07-08

Family

ID=23448582

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19830901672 Ceased EP0105360A4 (en) 1982-04-12 1983-04-12 ANTIBODIES WITH TWICE SPECIFICITY, THEIR PRODUCTION AND USE.

Country Status (11)

Country Link
EP (1) EP0105360A4 (fi)
JP (2) JPH0753119B2 (fi)
AT (1) AT394577B (fi)
AU (1) AU550486B2 (fi)
CA (1) CA1213229A (fi)
CH (1) CH672796A5 (fi)
ES (7) ES8504461A1 (fi)
FI (1) FI834529A0 (fi)
GB (4) GB2128631B (fi)
IT (1) IT1219778B (fi)
WO (1) WO1983003679A1 (fi)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3177776B2 (ja) * 1988-09-27 2001-06-18 武田薬品工業株式会社 ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
CA1214123A (en) * 1983-01-20 1986-11-18 Masashi Matsui Cell lines for use in the preparation of hybridoma cells
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
EP0467416A1 (en) * 1983-09-01 1992-01-22 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
JPH0617909B2 (ja) * 1984-04-23 1994-03-09 ボストン バイオメディカル リサーチ インスティテュート，インコーポレイテッド 双特異性抗体決定子
NL8501219A (nl) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic Immunologisch complex, de bereiding en toepassing daarvan.
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
JP2635343B2 (ja) 1986-04-14 1997-07-30 ザ・ジェネラル・ホスピタル・コーポレーション ヘテロ二官能性抗体および利用方法
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
US5053226A (en) * 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
EP0308936B1 (en) * 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
JPH02196799A (ja) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol 抗ヒト癌蛋白複合体
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
IT1235349B (it) * 1988-12-23 1992-06-30 Biodata Spa Saggio immunologico per determinazioni in fase omogenea
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
CA2006408A1 (en) * 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
WO1990012109A1 (en) * 1989-03-30 1990-10-18 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
FR2652004B1 (fr) * 1989-09-21 1994-10-28 Immunotech Partners Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
EP0515571B1 (en) * 1990-02-16 1998-12-02 Boston Biomedical Research Institute Hybrid reagents capable of selectively releasing molecules into cells
TW212184B (fi) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
EP0511011B1 (en) * 1991-04-26 1996-10-23 Surface Active Limited Novel antibodies and methods for their use
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
GB9421468D0 (en) * 1994-10-18 1994-12-07 Surface Active Ltd Biosensor
CA2266339A1 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
EP1740530B8 (en) 2004-03-16 2017-03-01 Temple University - Of The Commonwealth System of Higher Education Substituted phenoxy- and phenylthio-derivatives for treating proliferative disorders
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
EP2511299A1 (en) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
WO2007011968A2 (en) 2005-07-18 2007-01-25 Seattle Genetics, Inc. Beta-glucuronide-linker drug conjugates
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
EP2120915B1 (en) 2007-01-22 2011-09-28 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
KR102178606B1 (ko) 2013-03-15 2020-11-13 자임워크스 인코포레이티드 세포독성 및 유사분열-억제 화합물, 및 이를 사용하는 방법
WO2015053381A1 (ja) * 2013-10-10 2015-04-16 幸成 加藤 抗ポドプラニン抗体
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
CN113416229A (zh) 2014-09-17 2021-09-21 酵活有限公司 细胞毒性和抗有丝分裂化合物、及其使用方法
TWI618697B (zh) 2015-11-03 2018-03-21 財團法人工業技術研究院 化合物、連接子－藥物、及配體－藥物耦合體
CA3017527A1 (en) 2016-03-25 2017-09-28 Seattle Genetics, Inc. Process for the preparation of pegylated drug-linkers and intermediates thereof
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
JP2020512312A (ja) 2017-03-24 2020-04-23 シアトル ジェネティックス， インコーポレイテッド グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CA3110096A1 (en) * 2018-08-30 2020-03-05 Innovative Cellular Therapeutics CO., LTD. Chimeric antigen receptor cells for treating solid tumor
JP2022532192A (ja) 2019-05-10 2022-07-13 武田薬品工業株式会社 抗体薬物複合体
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
PE20231947A1 (es) 2020-11-09 2023-12-05 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco
AU2022304582A1 (en) 2021-06-29 2024-02-01 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130634A (en) * 1974-03-15 1978-12-19 University Of Illinois Foundation Method for detecting and quantifying antigens
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C.L. Reading on symposium on Hybridomas and Cellular Immortality, 5-6 Nov. 1981, Houston; in proceedings "Hybridomas and Cellular Immortality", Plenum Press 1983, Tom and Allison Eds.; *

Also Published As

Publication number Publication date
JPH0753119B2 (ja) 1995-06-07
ES8503441A1 (es) 1985-02-16
GB2167086A (en) 1986-05-21
AU1555983A (en) 1983-11-04
FI834529A (fi) 1983-12-09
ES537257A0 (es) 1986-04-01
EP0105360A1 (en) 1984-04-18
GB2169921B (en) 1987-03-04
AU550486B2 (en) 1986-03-20
AT394577B (de) 1992-05-11
IT1219778B (it) 1990-05-24
GB8530309D0 (en) 1986-01-22
ES521370A0 (es) 1985-04-16
ES527963A0 (es) 1985-02-16
GB2168998B (en) 1987-03-04
IT8320548A0 (it) 1983-04-12
ES8607386A1 (es) 1986-05-16
ES533930A0 (es) 1985-12-01
ES533931A0 (es) 1985-06-16
JP2562002B2 (ja) 1996-12-11
ATA901883A (de) 1991-10-15
ES8603080A1 (es) 1985-12-01
ES8504461A1 (es) 1985-04-16
ES538727A0 (es) 1986-02-01
ES8606655A1 (es) 1986-04-01
ES8506091A1 (es) 1985-06-16
FI834529A0 (fi) 1983-12-09
ES545247A0 (es) 1986-05-16
WO1983003679A1 (en) 1983-10-27
GB8530310D0 (en) 1986-01-22
GB2167086B (en) 1987-03-04
GB2168998A (en) 1986-07-02
GB8332646D0 (en) 1984-01-11
GB2128631A (en) 1984-05-02
ES8604424A1 (es) 1986-02-01
CA1213229A (en) 1986-10-28
JPS6312276A (ja) 1988-01-19
GB2128631B (en) 1987-02-25
GB2169921A (en) 1986-07-23
GB8530308D0 (en) 1986-01-22
CH672796A5 (fi) 1989-12-29
JPH0753600A (ja) 1995-02-28

Similar Documents

Publication Publication Date Title
EP0105360A4 (en) ANTIBODIES WITH TWICE SPECIFICITY, THEIR PRODUCTION AND USE.
AR242417A1 (es) Procedimiento para la preparacion de pirrolo-¡3,4-c¿-pirrolenos
DE3382383D1 (en) Interleukin-2-polypeptide.
ZA852438B (en) Antibodies,manufacture and use
AU4493685A (en) Polyclonal antibodies, preparation and use
DE3381294D1 (en) Brueckenwiderlager.
DE3382106D1 (en) Polyacetalharzmischungen.
CS149383A2 (en) Zpusob vyroby methylterc.butyletheru
EP0105346A4 (en) SYNTHETIC ANTIGEN OF PICORNAVIRUS.
DE3382031D1 (en) Polypeptide.
IL70968A (en) Urea-linked immunogens,their preparation and antibodies thereto
EP0122268A4 (en) STRUCTURED LINKS.
EP0131627A4 (en) SPECIFIC ANTIGENS OF THE CEA FAMILY (CARCINO-EMBRYONIC ANTIGEN), SPECIFIC ANTIBODIES OF THESE ANTIGENS AND THEIR METHODS OF USE.
AU1270583A (en) 3-azolyl-1,2-diaryl-1-halogenoprop-1-enes
AU563881B2 (en) Carbacycline, preparation and utilization thereof
IL69531A (en) Antibodies against bacterial peptidoglycans,their preparation and determination
IL83342A0 (en) Monoclonal antibodies,their preparation and their use
DE3381931D1 (en) Spruehvorrichtung.
AU618720B2 (en) Monoclonal antibodies
OA07604A (en) Improved melaminylthioarsenites.
AU1093783A (en) G.h. releasing peptide
EP0334958A4 (en) MONOCLONAL ANTIBODIES.
IE841235L (en) Immunological methods - enzyme preparations.
AU612122C (en) Monoclonal antibodies
IE820162L (en) Manufacturing antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19831210

AK Designated contracting states

Designated state(s): BE DE FR NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19860708

17Q First examination report despatched

Effective date: 19880606

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19931210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DAVID, GARY S.

Inventor name: FRINCKE, JAMES M.

Inventor name: ADAMS, THOMAS H.

Inventor name: MARTINIS, JOANNE

Inventor name: BARTHOLOMEW, RICHARD M.